TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05311085
Drug: Cytisine
Normalized name: Cytisine
DrugBank: Cytisine (DB09028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing of:~* days 1-3: one tablet (1.5mg) every two hours through the waking day (six tablets/day)~* days 4-12: one tablet every 2.5 hours (five tablets/day). Quit smoking date is day five.~* days 13-16: one tablet every three hours (four tablets/day)~* days 17-20: one tablet every 4-5 hours (three tablets/day)~* days 21-25: one tablet every six hours (two tablets/day)~Followed by a maintenance dose of cystine from day 26 to week 12 (one tablet every six hours: two tablets/day)
Study: NCT05311085
Drug: Nicotine delivered via an e-cigarette
Normalized name: Aldex AN
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pod device delivering nicotine. Nicotine strength: 30mg/ml (3%). Flavour: Tobacco
Study: NCT05948579
Drug: Intervention B Vilazodone Hydrochloride (HCl)
Normalized name: Vilazodone Hydrochloride
DrugBank: Vilazodone (DB06684)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vilazodone HCl will be administered at 10 mg once daily for 7 days, followed by 20 mg for 7 days, followed by 40 mg for the remainder of the trial. There must be a minimum of 7 days between dosage increases. One reduction in dose due to tolerability will be allowed. After Week 8, dose reduction for tolerability is allowed, but dose increase is not allowed.
Study: NCT06311942
Drug: HAIC plus PD-1 inhibitors plus lenvatinib
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients in the triple adjuvant therapy group received one cycle of HAIC about a month after liver resection, HAIC was adopted the FOFOLX6 program (Folinic acid+5-fluorouracil+Oxaliplatin). The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
Study: NCT06311942
Drug: PD-1 inhibitors plus lenvatinib
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The first cycle of PD-1 monoclonal antibody was administrated 2-4 weeks postoperatively, 200 mg IV, every 21 days for a total of 9 cycles. Lenvatinib was initiated orally 2-4 weeks postoperatively for 6 months.
Study: NCT06387329
Drug: Nitrofurantoin 100 MG
Normalized name: nitrofurantoin 100 MG
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No additional information
Study: NCT04527991
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT04527991
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT04527991
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT04527991
Drug: Vinflunine
Normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05265806
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will be assigned to administration of oxytocin intranasal spray (24 IU).
Study: NCT05265806
Drug: Oral oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each subject will be assigned to administration of oxytocin lingual spray (24 IU).
Study: NCT06578455
Drug: Cannabidiol (CBD) Powder
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 66.68 mg CBD per capsule for a total of 400 mg CBD per serving
Study: NCT06578455
Drug: Cannabidiol 100 MG/ML [Epidiolex]
Normalized name: cannabidiol 100 MG/ML [Epidiolex]
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 100 mg CBD/mL for a total of 400 mg CBD per serving
Study: NCT06577259
Drug: BMS-986435
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05915702
Drug: Gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT05915702
Drug: Gadoterate meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT05915702
Drug: Gadoteridol
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Approved standard of care macrocyclic GBCA, 0.1 mmol Gd/kg body weight, solution for intravenous injection, single dose
Study: NCT04850937
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The experimental group will be given 0.25mg/kg esketamine slowly intravenously after anesthesia induction
Study: NCT06013241
Drug: Brensocatib
Normalized name: Brensocatib
DrugBank: Brensocatib (DB15638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet.
Study: NCT06013241
Drug: Mometasone furoate nasal spray (MFNS)
Normalized name: mometasone furoate Nasal Spray
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal spray suspension.
Study: NCT05536804
Drug: Tirzepatide
Normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05569772
Drug: Semaglutide Pen Injector
Normalized name: semaglutide Pen Injector
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: maintenance dose of 1mg SC once weekly
Study: NCT04989946
Drug: Degarelix
Normalized name: Degarelix
DrugBank: Degarelix (DB06699)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: standard Gonadotropin-releasing hormone (GnRH) antagonist
Study: NCT04989946
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with multiple different types of cancer.
Study: NCT04989946
Drug: Cemiplimab
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab is a human PD-1 blocking antibody approved for the treatment of patients with non-small cell lung cancer, cutaneous squamous cell carcinoma, and locally advanced basal cell carcinoma.
Study: NCT04989946
Drug: Fianlimab
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphocyte activation gene-3 (LAG-3) is a protein that is upregulated on activated CD4+ and CD8+ T cells following T-cell receptor engagement. Binding of LAG-3 to MHC II on professional antigen-presenting cells suppresses the proliferation, activation, and cytokine secretion of T cells. Fianlimab is a human IgG4 antibody to lymphocyte activation gene-3 (LAG-3) that blocks LAG-3/MHC II-mediated T-cell inhibition.
Study: NCT06460506
Drug: IVA
Normalized name: Viva
DrugBank: Adenosine (DB00640)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granules for oral administration
Study: NCT06139107
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150mg twice a day for 3 cycles prior to radiation.
Study: NCT06578559
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 500 mg/sqm intravenous infusion over 120-minute at cycle 1 (if well tolerated, it is administered over 90 minutes at second administration, and over 60 minutes by the third administration) every 14 days.
Study: NCT06578559
Drug: Encorafenib
Normalized name: encorafenib
DrugBank: Encorafenib (DB11718)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 300 mg once daily (four 75 mg oral capsules).
Study: NCT06139107
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Letrozole 2.5mg daily
Study: NCT05697471
Drug: Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dienogest 2 mg per day
Study: NCT05697471
Drug: Danazol
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danzol 200MG per day
Study: NCT05189184
Drug: Camrelizumab+Apatinib mesylate+Albumin-bound paclitaxel+cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Camrelizumab in Combination With Apatinib mesylate Plus Albumin-bound paclitaxel and cisplatin as the First Line Treatment of Recurrent or Metastatic , UnresectableHead and Neck Squamous Cell Carcinoma (HNSCC)
Study: NCT06627413
Drug: Lumateperone Capsule
Normalized name: lumateperone Oral Capsule
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone 42 mg capsule, oral administration
Study: NCT06627413
Drug: Lumateperone LAI
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone LAI X500-E2 IM injection
Study: NCT06627413
Drug: Lumateperone LAI
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone LAI X500-E3 IM injection
Study: NCT06627413
Drug: Lumateperone LAI
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone LAI X500-X2 IM injection
Study: NCT06627413
Drug: Lumateperone LAI
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone LAI X500-X5 IM injection
Study: NCT06627413
Drug: Lumateperone LAI
DrugBank: Lumateperone (DB06077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lumateperone LAI (X500-E2 or X500-E3 or X500-X2 or X500-X5) IM injection
Study: NCT06576037
Drug: CBP-1019
Normalized name: CBPC
DrugBank: Carbenicillin (DB00578)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by vein (IV)
Study: NCT06576037
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein (IV)
Study: NCT06576037
Drug: 5-FLUOROURACIL
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by vein (IV)
Study: NCT06576037
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by vein (IV)
Study: NCT06576037
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by vein (IV)
Study: NCT06576037
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given by mouth
Study: NCT06558188
Drug: Romosozumab
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: romosozumab 210 milligrams monthly
Study: NCT06558188
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: teriparatide 20 micrograms daily
Study: NCT05426395
Drug: Vitamin B12 10 µg
Normalized name: vitamin B12 10 MG
DrugBank: Cyanocobalamin (DB00115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: There are two groups of women (n = 10 total) who will receive B12 dosing once daily, including group 2a (sufficient baseline B12, pregnant) and group 2b (insufficient baseline B12, pregnant).
Study: NCT05959616
Drug: Ciprofloxacin 500 mg
Normalized name: ciprofloxacin 500 MG
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (500 mg orally twice daily for three days),
Study: NCT05829148
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Comparison the effect of Dexmedetomidine, Melatonin and Pregabalin on hemodynamics, recovery profile and postoperative pain in patients undergoing Functional endoscopic sinus
Study: NCT05829148
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin
Study: NCT05261464
Drug: Metoprolol tartrate
Normalized name: Metoprolol Tartrate
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescribe oral metoprolol tartrate according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
Study: NCT05261464
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Prescribe oral ivabradine according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
Study: NCT05261464
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prescribe oral diltiazem immediate-release according to doses and time duration until patient reach targeted HR of less than 60 bpm or maximize dose according to each drug protocols prior to CCTA.
Study: NCT06119685
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD20 antibody therapy
Study: NCT06119685
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD38 antibody therapy
Study: NCT06119685
Drug: Interleukin-2
Normalized name: INTERLEUKIN-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune cytokine
Study: NCT04872257
Drug: Oral Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D 5,000 UI for 6 months (oral capsule, daily, single-dose)
Study: NCT06119685
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting chemotherapy
Study: NCT06119685
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemoprotectant
Study: NCT06119685
Drug: Isatuximab
Normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-CD38 antibody therapy
Study: NCT06574997
Drug: OCU400
Normalized name: OCU400
DrugBank: OCU400 (DB18277)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a subretinal injection of OCU400 modifier gene therapy product.
Study: NCT04920149
Drug: Mesalamine
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The IMP will be supplied as sachets with slow-releasing granules.
Study: NCT04972942
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)~2. Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~3. Maintenance: DARA every 4 weeks (Stop at Day +270)
Study: NCT05160493
Drug: S-ketamine and pregabalin
Normalized name: (S)-(-)-ketamine
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S-ketamine and pregabalin~* Drug: Pregabalin • 150mg (2hrs) pre operatively and 75mg twice daily post operatively for 7 days(POD1-7),followed by dose reduction to 75mg once daily for 7days(POD8-14)~* Drug: S-ketamine infusion • 0.5 mg/kg bolus after induction of anesthesia +0.12 mg/kg/h continuous intravenous infusion for 48 h
Study: NCT06263348
Drug: Dorzagliatin tablets
Normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.
Study: NCT05160493
Drug: Normal saline and placebo capsule
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline and placebo capsule
Study: NCT06475729
Drug: Citrate-Free Mirikizumab
Normalized name: Mirikizumab
DrugBank: Mirikizumab (DB14910)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT05638295
Drug: Sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05761951
Drug: DKN-01
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by IV (vein)
Study: NCT05761951
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given by IV (vein)
Study: NCT05425420
Drug: methadone hydrochloride 0.1mg/kg
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of methadone hydrochloride administered via intravenous (IV)
Study: NCT05120284
Drug: Dichloroacetate (DCA)
Normalized name: dichloroacetate
DrugBank: Dichloroacetic acid (DB08809)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study medication DCA is a liquid formulation mixed with an artificial sweetener containing aspartame and strawberry extract (50mg/mL)~Participants will be genotyped to determine GSTZ1 (glutathione S-transferase Zeta-1) haplotype status, which will stratify this group into 1 of 2 dose regimens:~EGT carriers will receive 12-14 mg/kg/12hr DCA. EGT non-carriers will receive 6-7 mg/kg/12 hr.
Study: NCT04771897
Drug: BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
Normalized name: Plasma Concentrate Factor IX
DrugBank: Factor IX Complex (Human) (DB11330)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 2, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
Study: NCT04781088
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04781088
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT06031012
Drug: CGECC combined with thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients received glutamine combined with thalidomide from the beginning of radiotherapy to one week after radiotherapy.
Study: NCT06246149
Drug: Tebentafusp
Normalized name: Tebentafusp
DrugBank: Tebentafusp (DB15283)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tebentafusp will be administered weekly i.v.
Study: NCT05072314
Drug: lidocaine 2% and 10%
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine infusion:~1. Commencing with an intravenous bolus after induction of anaesthesia, 0.125 ml/kg of lean body weight (LBW) of 2% lidocaine (2.5 mg/kg).\*~2. Followed by a 2% lidocaine intravenous infusion for the duration of surgery, 0.1665 ml/kg/h of LBW (3.33 mg/kg/hr).\*~3. A post-operative subcutaneous 0.0222 ml/kg/hr of LBW 10% lidocaine infusion for up to 24 hours thereafter (2.22 mg/kg/hr). Dosage will be capped at a maximum lean body weight of 68kg.~   * \*Day-case surgery receives intraoperative bolus and intraoperative infusion only
Study: NCT06219473
Drug: Fascia lata membrane
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
DrugBank: Octinoxate (DB09496)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: novel allogenic derived acellular matrix produced from human fascia lata allograft
Study: NCT06219473
Drug: Platlet Rich fibrin membrane
Normalized name: platelet glycoprotein VI
DrugBank: Fibrin (DB16604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich fibrin (PRF) or leukocyte- and platelet-rich fibrin (L-PRF) is a derivative of PRF where autologous platelets and leukocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue
Study: NCT05367388
Drug: APL-101
Normalized name: APL-502
DrugBank: APL-502 (DB17473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: APL-101 (Vebreltinib) is an orally available small molecule, which is a tyrosine kinase inhibitor (TKI) for the mesenchymal epithelial transition protein tyrosine kinase receptor (c-Met) with high selectivity and potency.~The treatments to be administered in this study include:~• Treatment A (reference): Two 100 mg APL-101 (Vebreltinib) capsules (200 mg dose), manufactured for Apollomics, Inc.
Study: NCT05367388
Drug: PLB-1001
DrugBank: LB-100 (DB15412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLB-1001 (Bozitinib) is a chemical drug category 1.1 innovative drug. It is a highly effective and highly selective c-Met tyrosine kinase inhibitor.~The treatments to be administered in this study include:~• Treatment P (test): Two 100 mg PLB-1001 (Bozitinib) capsules (200 mg dose), manufactured for Beijing Pearl Biotechnology Co., Ltd.
Study: NCT05089734
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT05203445
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 300 mg orally BID
Study: NCT05203445
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 400 mg intravenously q6weeks
Study: NCT05305794
Drug: Insulin + semaglutide treatment
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Usual insulin treatment + semaglutide (0.25 mg/week for 4 weeks, then 0.50 mg/week for 4 weeks, then 1 mg/week for 18 weeks, i.e. a total duration of 26 weeks). Upon introduction of semaglutide (ozempic) treatment, insulin doses will be reduced by 10% (basal insulin, basal rate and bolus)
Study: NCT05305794
Drug: Usual insulin treatment
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual insulin treatment